Tamsulosin Hydrochloride Capsule
Product Images NDC 68084-299

9 FDA label images from American Health Packaging · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 68084-299). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

84a16c87 6397 1d47 E053 2a91aa0a30e8

84a16c87 6397 1d47 E053 2a91aa0a30e8
Tamsulosin Hydrochloride 0.4 mg oral capsules, showing three views of a yellow and white capsule imprinted with partial markings including "ZA-18" and the dosage strength. The image includes a millimeter scale for size reference.*
FDA Label Image

Blister

Blister
Multiple identical white label strips for Tamsulosin Hydrochloride Capsule USP 0.4 mg, an oral capsule dosage form. Each label includes the drug name, strength, a barcode, expiration date (represented as 'XXXX/XX'), lot number, National Drug Code (NDC) 68084-299-11, and American Health Packaging as the labeler based in Columbus, Ohio.*
FDA Label Image

Carton

Carton
Tamsulosin Hydrochloride 0.4 mg capsules, USP, oral dosage form, with a package size of 100 capsules (10 x 10). Label includes NDC 68084-299-01, barcode, pharmacist dispensing instructions, storage conditions, dosage reference, safety warnings, and packaging information by American Health Packaging, Columbus, Ohio.*
FDA Label Image

Figure 1

Figure 1
A pharmacokinetic line graph showing plasma concentration (ng/mL) over time (hours) up to 36 hours for Tamsulosin Hydrochloride. Two curves compare plasma levels under fasted (dashed line) and fed (solid line) conditions, illustrating differences in absorption and concentration over time.*
FDA Label Image

Figure 2a

Figure 2a
A line graph depicting mean change over duration of treatment in weeks for Tamsulosin Hydrochloride at 0.4 mg and 0.8 mg doses compared to placebo. The x-axis shows treatment duration from baseline to 13 weeks and LOCF, while the y-axis indicates mean change values. Three lines represent the 0.8 mg dose, 0.4 mg dose, and placebo results.*
FDA Label Image

Figure 2b

Figure 2b
A line graph showing mean change over time for three groups during a 13-week treatment period, with group sizes noted at multiple time points. The groups are 0.8 mg dose, 0.4 mg dose, and placebo, indicated respectively by circles, triangles, and squares. The y-axis represents mean change, and the x-axis represents duration of treatment in weeks, including a last observation carried forward (LOCF) measure.*
FDA Label Image

Figure 3a

Figure 3a
Line graph showing mean change in mL/sec over duration of treatment in weeks for three groups: 0.8 mg, 0.4 mg Tamsulosin Hydrochloride, and placebo. The graph includes data points from baseline through 13 weeks and a last observation carried forward (LOCF) endpoint, illustrating treatment effects over time for the two active doses compared to placebo.*
FDA Label Image

Figure 3b

Figure 3b
A line graph displaying the mean change in mL/sec over treatment duration in weeks for three groups: Tamsulosin Hydrochloride 0.8 mg, 0.4 mg, and placebo. The graph plots mean changes from baseline to 13 weeks and last observation carried forward (LOCF), showing higher improvement in flow rate with Tamsulosin 0.8 mg and 0.4 mg compared to placebo.*
FDA Label Image

Structure

Structure
Chemical structure diagram of Tamsulosin Hydrochloride, showing the molecular arrangement including aromatic rings, sulfonamide, methoxy, and hydrochloride components.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.